Adverse effects/events: death ‐ all‐cause mortality(assessed by patient records) · recent‐onset psychosis
Extended specialised early intervention (SEI) teams showed no clear difference in adverse effects/events: death ‐ all‐cause mortality(assessed by… compared with standard SEI teams plus treatment (low certainty).
1 finding from 1 review
Functioning: average endpoint score on specific functioning scale(assessed by structured interview) · recent‐onset psychosis
1 finding from 1 review
Primary outcomes · infants at risk for, or having early symptoms consistent with, opioid withdrawal
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
– Modifying environmental stimulation · infants at risk for, or having early symptoms consistent with, opioid withdrawal
1 finding from 1 review
– Feeding practices · infants at risk for, or having early symptoms consistent with, opioid withdrawal
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
– Support of the mother‐infant dyad · infants at risk for, or having early symptoms consistent with, opioid withdrawal
1 finding from 1 review
Admission to NICU (primary outcome)№ of participants: 204(1 RCT) · infants at risk for, or having early symptoms consistent with, opioid withdrawal
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mortality ‐ early and intermediate · people requiring treatment for chronic DVT
1 finding from 1 review
Recurrent VTE · people requiring treatment for chronic DVT
Chronic DVT ‐ antiplatelet agents plus BMP may leads to lower recurrent VTE ‐ early, intermediate and long term compared with BMP plus placebo (low certainty).
1 finding from 1 review
Mortality ‐ early and intermediate · people requiring treatment for acute DVT
1 finding from 1 review
Recurrent VTE ‐ early and intermediate · people requiring treatment for chronic DVT
It is very uncertain whether chronic DVT ‐ antiplatelet agents plus BMP changes recurrent VTE ‐ early and intermediate compared with BMP alone (very low certainty).
1 finding from 1 review
Failed Treatment · preterm infants
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects sufficient to stop treatment · pregnant women at increased risk of VTE during pregnancy and the early postnatal period
It is very uncertain whether antenatal (± postnatal) prophylaxis: LMWH changes adverse effects sufficient to stop treatment compared with UFH (very low certainty).
1 finding from 1 review
Adverse effects sufficient to stop treatment · women with varicose veins before birth, having a caesarean (elective or emergency) or vaginal birth
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects sufficient to stop treatment · women giving birth by elective or emergency caesarean (elective only (1 trial), emergency or elective (4 trials))
1 finding from 1 review
Complications and side effects · Bell's palsy
It is very uncertain whether surgery for Bell's palsy changes side effects and complications of treatmentMeasured by clinical… compared with medical treatment (oral prednisolone) or no treatment (very low certainty).
1 finding from 1 review
Depression remission · women of any age, with PND up to 12 months
It is very uncertain whether antidepressants changes depression remission (early phase, < 5 weeks) compared with treatment (very low certainty).
1 finding from 1 review
RR 2.31 [1.5, 3.54]
Studies not reported
Very low
Depression severity ‐ mean EPDS score (early phase, < 5 weeks) · women of any age, with PND up to 12 months
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Treatment adherence (defined as dose delay) ( · adjuvant therapy for early breast cancer
Taxane followed by anthracyclines showed no clear difference in treatment adherence (defined as dose delay) ( compared with anthracyclines followed by taxane (moderate certainty).
1 finding from 1 review
Treatment adherence (defined as dose reduction) ( · neoadjuvant therapy for early breast cancer
Taxane followed by anthracyclines showed no clear difference in treatment adherence (defined as dose reduction) ( compared with anthracyclines followed by taxane (moderate certainty).
1 finding from 1 review